Ryan Savitz's most recent trade in Dianthus Therapeutics Inc was a trade of 150,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 3, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Dianthus Therapeutics Inc | Ryan Savitz | EVP, CFO & CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2026 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Ryan Savitz | CFO & CBO | Sale of securities on an exchange or to another person at price $ 45.18 per share. | 04 Dec 2025 | 20,000 | 0 | - | 45.2 | 903,600 | Common Stock |
| Dianthus Therapeutics Inc | Ryan Savitz | CFO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.44 per share. | 04 Dec 2025 | 20,000 | 20,000 | - | 8.4 | 168,800 | Common Stock |
| Dianthus Therapeutics Inc | Ryan Savitz | CFO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2025 | 20,000 | 84,766 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Ryan Savitz | CFO & CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Sep 2025 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Ryan Savitz | CFO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2025 | 20,000 | 104,766 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Ryan Savitz | CFO & CBO | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 09 Sep 2025 | 20,000 | 0 | - | 35 | 700,000 | Common Stock |
| Dianthus Therapeutics Inc | Ryan Savitz | CFO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.44 per share. | 09 Sep 2025 | 20,000 | 20,000 | - | 8.4 | 168,800 | Common Stock |
| Dianthus Therapeutics Inc | Ryan Savitz | CFO & CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Ryan Savitz | CFO & CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Ryan Savitz | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) |